zurück

Amivantamab (non-small cell lung cancer (NSCLC), EGFR exon 20 insertion mutations, after platinum-based therapy)

Subject:

  • Active Substance: Amivantamab
  • Name: Rybrevant®
  • Therapeutic area: Non-small cell lung cancer (NSCLC)
  • Pharmaceutical company: Janssen-Cilag GmbH

Time table:

  • Start: 15.01.2022
  • Final decision by G-BA: 07.07.2022

Final decision:

  • Patients who are eligible for another chemotherapy:
    • No additional benefit proved
  • Patients who are not eligible for another chemotherapy:
    • No additional benefit proved